Clinical trials recruiting in Huzhou, China

Phase breakdown

Conditions recruiting in Huzhou, China

Recruiting trials in Huzhou, China

• A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM
  NCT07667803 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus
  NCT07662044 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)
  NCT07286175 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• A Study of Brenipatide in Adult Participants With Major Depressive Disorder
  NCT07412756 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
  NCT07392190 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of MI078 for Postpartum Depression
  NCT07721961 · Phase: Phase 3 · Ages: 18 Years to 45 Years · Sex: Female
• A Study to Evaluate 9MW1911 in Patients With Chronic Obstructive Pulmonary Disease (COPD)
  NCT07292714 · Phase: Phase 2 · Ages: 40 Years to 75 Years · Sex: All (male and female)
• A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus
  NCT07776509 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 Diabetes
  NCT07670416 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
  NCT06989437 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Test Whether BI 3034701 Helps People to Lose Weight Who Live With Obesity or Overweight
  NCT07662122 · Phase: Phase 2 · Ages: 18 Years to 74 Years · Sex: All (male and female)
• AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea
  NCT07571005 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications
  NCT07797335 · Phase: Phase 3 · Ages: 45 Years and older · Sex: All (male and female)
• China HeadAche DIsorders RegiStry
  NCT05334927 · Phase: Not specified · Ages: 12 Years and older · Sex: All (male and female)
• Clinical Study on the Treatment of Stable Bronchiectasis With Bailing Capsules Combined With Guben Kechuan Granules
  NCT07114120 · Phase: Phase 4 · Ages: 18 Years to 80 Years · Sex: All (male and female)
• Durvalumab Consolidation After Chemoradiation Therapy for Limited Stage SCLC in China
  NCT07161388 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
  NCT07190222 · Phase: Phase 3 · Ages: 40 Years to 80 Years · Sex: All (male and female)
• Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Systemic Lupus Erythematosus
  NCT05688696 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• IASO-782 in Systemic Lupus Erythematosus
  NCT07483346 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy
  NCT06862869 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• Segmentectomy Versus Lobectomy for Lung Adenocarcinoma ≤ 2cm
  NCT04937283 · Phase: Not applicable (e.g. observational or device study) · Ages: 20 Years to 79 Years · Sex: All (male and female)
• Study on the Prevention of Atrial Fibrillation Recurrence After Ablation by Qidong Yixin Granule
  NCT07508618 · Phase: Phase 4 · Ages: 18 Years to 80 Years · Sex: All (male and female)
• The Efficacy and Safety of Combining Probiotic VSL#3 With Vedolizumab for the Treatment of Moderate Ulcerative Colitis
  NCT06609447 · Phase: Phase 4 · Ages: 18 Years to 85 Years · Sex: All (male and female)
• This is a Non-interventional, Study to Assess Demographic Characteristics and Patient Reported Outcomes in China Patients With SEA Treated With Benralizumab
  NCT06862206 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female)
• To Evaluate the Efficacy and Safety of SG301 SC Injection in Systemic Lupus Erythematosus
  NCT07447986 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female)

Common questions

How many clinical trials are recruiting in Huzhou, China?

25 recruiting trials have at least one study site in Huzhou, China.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.